blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4245320

EP4245320 - METHODS AND COMPOSITIONS FOR IMMUNE PROTECTION AGAINST EXTRA-INTESTINAL PATHOGENIC E. COLI [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  03.05.2024
Database last updated on 31.08.2024
FormerThe application has been published
Status updated on  18.08.2023
Most recent event   Tooltip05.07.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
GlaxoSmithKline Biologicals S.A.
Rue de l'Institut, 89
1330 Rixensart / BE
For all designated states
Janssen Pharmaceuticals, Inc.
1125 Trenton-Harbourton Road
Titusville, NJ 08560 / US
[2023/38]
Inventor(s)01 / POOLMAN, Jan Theunis
2011 CT Haarlem / NL
02 / ABBANAT, Darren Robert
New York, 12518 / US
03 / YON, Patricia Ibarra
4112 Solothum / CH
04 / HERMANS, Peter Wilhelmus
6852 PG Huissen / NL
05 / KOWARIK, Michael Thomas
8055 Zurich / CH
06 / WETTER, Michael Lukas
8047 Zurich / CH
07 / KEMMLER, Stefan Jochen
8048 Zurich / CH
08 / HAUPTLE, Micha Andres
8952 Zurich-Schlieren / CH
09 / GAMBILLARA, Veronica
8706 Meilen / CH
10 / MALLY, Manuela
8105 Watt / CH
11 / JACQUEMYN, Bert
2800 Mechelen / BE
 [2023/38]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[2023/38]
Application number, filing date23176994.424.08.2016
[2023/38]
Priority number, dateUS201562209091P24.08.2015         Original published format: US 201562209091 P
US201562210655P27.08.2015         Original published format: US 201562210655 P
[2023/38]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP4245320
Date:20.09.2023
Language:EN
[2023/38]
Type: A3 Search report 
No.:EP4245320
Date:22.11.2023
Language:EN
[2023/47]
Search report(s)(Supplementary) European search report - dispatched on:EP23.10.2023
ClassificationIPC:A61K39/02, C08B37/00, A61K39/00, A61K39/108, A61K47/64, A61P31/04
[2023/47]
CPC:
A61K39/0258 (EP,IL,KR,US); A61K39/00 (IL); A61K39/385 (US);
A61K47/6415 (EP,KR,US); A61K47/646 (EP,KR,US); A61P29/00 (KR);
A61P31/04 (EP,US); C08B37/0063 (EP,IL,KR,US); A61K2039/545 (EP,IL,KR,US);
A61K2039/55583 (EP,IL,KR,US); A61K2039/6037 (EP,IL,KR,US); A61K2039/6087 (EP,IL,KR,US);
A61K2039/70 (EP,IL,KR,US); Y02A50/30 (EP,US) (-)
Former IPC [2023/38]A61K47/64
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2024/23]
Former [2023/38]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN ZUM IMMUNSCHUTZ GEGEN EXTRAINTESTINALE PATHOGENE E. COLI[2023/38]
English:METHODS AND COMPOSITIONS FOR IMMUNE PROTECTION AGAINST EXTRA-INTESTINAL PATHOGENIC E. COLI[2023/38]
French:MÉTHODES ET COMPOSITIONS POUR UNE PROTECTION IMMUNITAIRE CONTRE E. COLI PATHOGÈNE EXTRA-INTESTINALE[2023/38]
Examination procedure29.04.2024Amendment by applicant (claims and/or description)
29.04.2024Examination requested  [2024/23]
29.04.2024Date on which the examining division has become responsible
Parent application(s)   TooltipEP16760616.9  / EP3341016
Fees paidRenewal fee
02.06.2023Renewal fee patent year 03
02.06.2023Renewal fee patent year 04
02.06.2023Renewal fee patent year 05
02.06.2023Renewal fee patent year 06
02.06.2023Renewal fee patent year 07
02.06.2023Renewal fee patent year 08
04.07.2024Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO2009104074  (GLYCOVAXYN AG [CH], et al) [A] 1-12 * page 17, lines 3-11 * * claims 25, 26 * * example 10 * * claims 5,8 * * page 22, lines 29-30 *;
 [A]WO2014037585  (GLYCOVAXYN AG [CH]) [A] 1-12 * paragraph [0007] * * paragraph [0009] * * paragraph [0014] *;
 [AP]WO2015124769  (GLYCOVAXYN AG [CH]) [AP] 1-12 * page 103 - page 104; table 6 * * examples 9, 11, 12 * * claims 1, 4, 5, 6 * * paragraph [0264] *;
 [A]  - A. CROSS ET AL, "Safety And Immunogenicity Of A Polyvalent Escherichia Coli Vaccine In Human Volunteers", JOURNAL OF INFECTIOUS DISEASES. JID, CHICAGO, IL., (19941001), vol. 170, no. 4, doi:10.1093/infdis/170.4.834, ISSN 0022-1899, pages 834 - 840, XP055311603 [A] 1-12 * abstract * * page 834, column r, paragraph 5 - page 835, column l, paragraph 1 * * table 2 * * table 3 *

DOI:   http://dx.doi.org/10.1093/infdis/170.4.834
 [A]  - CRYZ S J ET AL, "Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine", VACCINE, ELSEVIER LTD, GB, (19950101), vol. 13, no. 5, doi:10.1016/0264-410X(94)00009-C, ISSN 0264-410X, pages 449 - 453, XP004057719 [A] 1-12 * abstract * * page 450, column r, paragraph 3 *

DOI:   http://dx.doi.org/10.1016/0264-410X(94)00009-C
 [A]  - MARIO F FELDMAN ET AL, "Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 102, no. 8, doi:10.1073/PNAS.0500044102, ISSN 0027-8424, (20050222), pages 3016 - 3021, (20050209), XP009121034 [A] 1-12 * abstract *

DOI:   http://dx.doi.org/10.1073/pnas.0500044102
 [A]  - B. A. ROGERS ET AL, "Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, (20110101), vol. 66, no. 1, doi:10.1093/jac/dkq415, ISSN 0305-7453, pages 1 - 14, XP055056619 [A] 1-12 * abstract *

DOI:   http://dx.doi.org/10.1093/jac/dkq415
 [AP]  - VAN DEN DOBBELSTEEN GERMIE P J M ET AL, "Immunogenicity and safety of a tetravalentE. coliO-antigen bioconjugate vaccine in animal models", VACCINE, ELSEVIER LTD, GB, (20160706), vol. 34, no. 35, doi:10.1016/J.VACCINE.2016.06.067, ISSN 0264-410X, pages 4152 - 4160, XP029644969 [AP] 1-12 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.vaccine.2016.06.067
by applicantGB2220211
 US5057540
 WO2006119987
 WO2007109812
 WO2007109813
 WO2009104074
 WO2014057109
 WO2015124769
    - JOHNSON et al., J Lab Clin Med, (20020000), vol. 139, no. 3, pages 155 - 162
    - KOHLER et al., Int J MedMicrobiol, (20110000), vol. 301, no. 8, pages 642 - 647
    - FOXMAN, Am J Med, (20020000), vol. 1A, pages 5S - 13S
    - RUSSO et al., Microbes Infect, (20030000), vol. 5, no. 5, pages 449 - 456
    - SCHITO et al., Int. J. Antimicrob. Agents, (20090000), vol. 34, no. 5, pages 407 - 413
    - PITOUT et al., Expert Rev. Anti. Infect. Ther, (20120000), vol. 10, no. 10, pages 1165 - 1176
    - JOHNSON et al., Antimicrob Agents Chemother, (20100000), vol. 54, no. 1, pages 546 - 550
    - ROGERS et al., J Antimicrob Chemother, (20110000), vol. 66, no. 1, pages 1 - 14
    - ROGERS et al., Antimicrob Agents Chemother. 2014, (20110000), vol. 58, no. 9, pages 4997 - 5004
    - STENUTZ et al., FEMS Microbial Rev, (20060000), vol. 30, pages 382 - 403
    - RUSSO et al., Vaccine, (20070000), vol. 25, pages 3859 - 3870
    - LIPSITCH, Emerging Infectious Diseases, (19990000), vol. 5, pages 336 - 345
    - STOUTE et al., N. Engl. J. Med, (19970000), vol. 336, pages 86 - 91
    - IHSSEN et al., Microbial Cell Factories, (20100000), vol. 9, no. 61, page 61
    - LUKAC et al., Infect Immun, (19880000), vol. 56, pages 3095 - 3098
    - HO et al., Hum Vaccin, (20060000), vol. 2, pages 89 - 98
    - PAWLOWSKI et al., vaccine, (20000000), vol. 18, pages 1873 - 1885
    - ROBBINS et al., Proc Natl Acad Sci USA, (20090000), vol. 106, pages 7974 - 7978
    - SARASWAT et al., Biomed. Res. Int, (20130000), pages 1 - 18
    - DATSENKOWANNER, Proc Natl Acad Sci USA, (20000000), vol. 97, pages 6640 - 6645
    - KIM et al., Clin Diagn Lab Immunol, (20030000), vol. 315, no. 4, pages 616 - 145
    - JOHNSON et al., JLab Clin Med, (20020000), vol. 139, no. 3, pages 155 - 162
    - ROGERS et al., JAntimicrob Chemother, (20110000), vol. 66, no. 1, pages 1 - 14
    - BANERJEE et al., Antimicrob Agents Chemother, (20140000), vol. 58, no. 9, pages 4997 - 5004
    - PAWLOWSKI et al., Vaccine, (20000000), vol. 18, pages 1873 - 1885
 WO2007US64857
 WO2007US64858
 WO2015EP53739
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.